News

Carvana Stock Update: Analyst Upgrades Shares

1 Mins read

Carvana stock has been on a remarkable run this year, with a surge of 1,000%. Despite this impressive performance, Wedbush analyst Seth Basham has decided to upgrade the company’s shares.

Carvana experienced some turbulence earlier, but a recent debt exchange provided a much-needed lifeline. It is this debt exchange that motivated Basham to upgrade Carvana stock from Underperform to Neutral. He believes that the debt exchange will grant the company “at least two years of breathing room to execute.” Additionally, Carvana’s profitability has been improving, which could lead to better-than-expected earnings in the third and fourth quarters.

However, Basham did not elevate the stock to Outperform. One reason for his cautious approach is the company’s expectation of a $600 to $1,100 improvement in gross profit per unit (GPU) compared to 2021. The analyst deems this estimate to be too high. Furthermore, Carvana’s earnings before interest, taxes, depreciation, and amortization (EBITDA) are anticipated to face pressure in 2024 when the company decides to shift its focus back to growth.

It is important to exercise caution when considering Carvana stock, even without these fundamental factors. The shares have already gained an impressive 1,001% in 2023, suggesting that some consolidation may be needed for the company to sustain its turnaround.

In premarket trading, Carvana stock has risen by 0.8% to $52.60 as of 7:59 a.m.

Contact and subscription information has been removed for a cleaner reading experience.

Related posts
News

First Solar Inc. Financial Report

1 Mins read
First Solar Inc. saw its shares rise more than 5% during the extended session on Tuesday, showing investor optimism for the future…
News

AMC Entertainment Holdings Inc. Quarterly Results Awaited

1 Mins read
Shares of AMC Entertainment Holdings Inc. have surged 5.9% on Tuesday, marking a three-day winning streak and the largest daily percentage increase…
News

Theratechnologies FDA Rejection

1 Mins read
Theratechnologies is poised for a significant setback as the Food and Drug Administration (FDA) has rejected its supplemental biologics license application for…

Leave a Reply

Your email address will not be published. Required fields are marked *

28 − 24 =